Advancing drug development using in silico modeling

June 22, 2022

The technologic and pharmacologic advances that have enabled researchers to take aim at previously untreatable diseases have contributed to an increase in the number of molecules in the development pipeline that are challenging and difficult to manufacture.

Spotlight

ERT

ERT is a global data and technology company that minimizes uncertainty and risk in clinical trials so that our customers can move ahead with confidence. With more than 40 years of clinical and therapeutic experience, we balance knowledge of what works with a vision for what’s next, so we can adapt without compromising standards.

OTHER WHITEPAPERS

How IPD Can Deliver for Life Sciences

whitePaper | January 1, 2020

Life sciences is facing a number of disruptors: novel cell and gene therapies that will revolutionize manufacturing, drug delivery and pricing models; a battle for the best and brightest talent; political and public pressure on the price of medication as well as the implications of the fourth industrial revolution. These factors combine to make investment decisions more challenging. With life sciences firms placing an increasing focus on the most efficient use of capital and shorter delivery times, project delivery providers are striving to come up with leaner and more innovative strategies and solutions to meet these needs. Integrated Project Delivery (IPD) is one such strategy.

Access to medicinal products

whitePaper | January 3, 2022

There are many factors that can prevent a patient from being able to obtain the medicine they need, ranging from selective marketing decisions by companies to products being too expensive or pharmacy stock-outs

National Council for Prescription Drug Programs

whitePaper | May 12, 2022

Advancements in Drug Development and Formulation

whitePaper | December 13, 2022

A recent e-symposium presented insights into the latest research and innovative solutions to help shorten timeto-market, reduce development costs, increase yield, and assure quality and pharmacopoeia compliance throughout the drug development process.

The true impact of machine failure in pharma

whitePaper | November 24, 2022

Today’s pharmaceutical industry is facing big expectations and opportunities. Tasked with developing and manufacturing effective therapeutics and vaccines for an ongoing global pandemic,

Deal-Making Roundup

whitePaper | November 19, 2022

In the second year of the pandemic, dealmaking continued to take place at record levels, maintaining much of the momentum created during 2020.